Hou 2013.

Methods	Study design: Randomised clinical trial Study duration: January 2008 to December 2012 Duration of follow‐up: 1 month Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by images or liver biopsy; with liver function of Child‐Pugh Class A or B; adequate renal function; expected survival > 3 months Age (mean, range): 52.3 years, 32‐72 years Male (n/total): 34/42 Child‐Pugh Class A‐B: 42 patients
Interventions	TACE + cryoablation group (n = 22): TACE: Chemotherapeutic drugs: theprubicin 20‐40 mg, 5‐fluorouracil 1‐1.5 g, and cisplatin 60‐80 mg. TACE treatment was performed 2‐4 times with an interval of 4 weeks. Cryoablation: The temperature was 40℃ or ‐150℃. Cryoablation was performed 1‐2 times. TACE group (n = 20): Chemotherapeutic drugs: theprubicin 20‐40 mg, 5‐fluorouracil 1‐1.5 g, and cisplatin 60‐80 mg TACE was performed at 2‐4 weeks.
Outcomes	Tumour response: measured by image examinations at 4 weeks after treatment Serum level of AFP Immune function
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.